Terms: = Thyroid cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
10 results:
1. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered thyroid cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
2. Development and validation of a nomogram for risk of pulmonary metastasis in non-papillary thyroid carcinoma: A SEER-based study.
Li Y; Gao X; Guo T; Liu J
Medicine (Baltimore); 2023 Aug; 102(32):e34581. PubMed ID: 37565907
[TBL] [Abstract] [Full Text] [Related]
3. D898_E901
Porcelli T; Moccia M; De Stefano MA; Ambrosio R; Capoluongo E; Santoro M; Hadoux J; Schlumberger M; Carlomagno F; Salvatore D
JCO Precis Oncol; 2023 Aug; 7():e2300052. PubMed ID: 37535881
[TBL] [Abstract] [Full Text] [Related]
4. [Retrospective study of thyroid invasion and central lymph node metastasis in 124 patients with hypopharyngeal carcinoma].
Liu HF; Huang ZG; Fang JG; Chen XH; Zhang Y; Hou LZ; Ma HZ; Guo W; Zhong Q
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Sep; 56(9):956-961. PubMed ID: 34666444
[No Abstract] [Full Text] [Related]
5. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
[TBL] [Abstract] [Full Text] [Related]
6. Overexpression of ccne1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis.
Yuan Q; Zheng L; Liao Y; Wu G
World J Surg Oncol; 2021 Mar; 19(1):86. PubMed ID: 33757543
[TBL] [Abstract] [Full Text] [Related]
7. Development and Internal Validation of a Predictive Model for Individual cancer Risk Assessment for thyroid Nodules.
San Laureano FC; Alba JJF; Heras JMJ; Millán AIJ; Fernández-Ladreda MT; Ortega MDCA
Endocr Pract; 2020 Oct; 26(10):1077-1084. PubMed ID: 33471709
[TBL] [Abstract] [Full Text] [Related]
8. The clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients.
Sezer H; Demirkol MO; Yazici D; Kapran Y; Alagöl MF
Turk J Med Sci; 2020 Apr; 50(2):360-368. PubMed ID: 31999407
[TBL] [Abstract] [Full Text] [Related]
9. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract] [Full Text] [Related]
10. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges.
Shin JE; Baek JH; Lee JH
Curr Opin Oncol; 2013 Jan; 25(1):14-9. PubMed ID: 23079931
[TBL] [Abstract] [Full Text] [Related]
